BIIB Faces FDA Panel Tomorrow, CRSP Climbs On Hemoglobinopathies Trial Data, SAVA On Watch

Today's Daily Dose brings you news about FDA's briefing information related to Biogen's Alzheimer's drug candidate ahead of the panel vote, CRISPR/Vertex Pharma's early data from their two ongoing phase I/II clinical trials of CTX001 in severe hemoglobinopathies, and Cassava's additional data from its phase IIb study with Alzheimer's drug candidate Sumifilam.

from RTT - Biotech https://ift.tt/32h6K3o
via IFTTT